UPC Analytics
DEEN
Übersicht · Eingereicht: 7. Juli 2023

UPC_CFI_230/2023

SYSTEMS AND METHODS FOR DISPLAY DEVICE AND SENSOR ELECTRONICS UNIT COMMUNICATION

VerletzungHauptverletzungsklageParis LDInfringementCase Closed
Parteien

Kläger

Vertreter: Anne-Charlotte le Bihan (Bird & Bird AARPI); Laurent Labatte (Bird & Bird AARPI); David Sproston (Hoffmann Eitle); Mark Jones (Hoffmann Eitle)

Beklagte

Vertreter: Christian Dekoninck (Taylor Wessing N.V.); Gisbert Hohagen (TaylorWessing Partnerschaftsgesellschaft mbB); François Pochart (August Debouzy); Eelco Bergsma (Taylor Wessing N.V.)
Richter

Französische Kammer — Einzelrichter anonymisiert.

  • Panel member (anonymized)
  • Panel member (anonymized)
  • Panel member (anonymized)
  • Panel member (anonymized)
Patente
  • EP3435866
  • EP 3 435 866
CPC-Codes: A61B5/4839, A61B5/14865, A61B5/6898, A61B2560/0252, H04L67/12, G16H40/63, A61B5/0015, G16H40/60, A61B5/1116, A61B5/0004, A61B5/14532, A61B5/14546

Technologiebereich: Medical Devices · CGM

Sektor: Healthcare Informatics

Ausgang
Nichtig erklärtAbgewiesen — Patent ungültig
Eingereicht: 7. Juli 2023
Erste Entscheidung: 19. Dez. 2023
Letzte Entscheidung: 4. Juli 2024
Sprache: English

Decision on the merits by Paris Local Division (4 July 2024). EP 3 435 866 B1 (analyte monitoring / continuous glucose monitoring system) was entirely revoked for lack of inventive step; auxiliary requests 1 and 2 were also invalid (added subject-matter). DexCom's infringement action was dismissed in full. DexCom was ordered to bear costs. The court addressed jurisdiction on the revocation counterclaim, the carve-out under Art. 83 UPCA, claim interpretation, novelty and inventiveness.

Im UPC-Register öffnen
Ansprüche
Streitig1, 2, 3, 4, 5, 6, 7, 8, 9
Nichtig erklärtall
Hinweise: EP 3 435 866 B1 entirely revoked; claim 1 lacked inventive step; dependent claims 2-9 also challenged and not defended with specific arguments; auxiliary requests 1 and 2 also invalid.